Literature DB >> 378500

Dosage adjustment from simple nortriptyline spot level predictor tests in depressed patients.

S A Montgomery, R McAuley, D B Montgomery, R A Braithwaite, S Dawling.   

Abstract

20 routine patients with endogenous depression were investigated in a kinetic and 4 week treatment study. Steady-state plasma nortriptyline concentrations above 200 microgram/L were associated with a highly significant poorer therapeutic outcome. The correlations between the 24, 48 and 72 hour concentrations and steady-state concentration were very good (r = 0.81, 0.97, 0.94; p less than 0.0001) and better than the correlation between half-life and steady-state (r = 0.65; p less than 0.01). The Spearman rank correlations (Rs) between amelioration of depression measured by the Hamilton Rating Scale (HRS) and the 24, 48 and 72 hour concentrations were highly significant (Rs = 0.74, 0.79, 0.79; p less than 0.001) but for half-life (Rs = 0.33) the correlation was not significant. The single 48 hour plasma nortriptyline concentration following a single oral dose is recommended as a reliable simplified monitoring test suitable for a busy clinic. The test is useful for dosage adjustment to maximise antidepressant action and minimise toxicity. A tentative dosage adjustment schedule for individualising antidepressant treatment with nortriptyline based on the 48 hour or the 24 hour plasma concentration is proposed.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 378500     DOI: 10.2165/00003088-197904020-00005

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  10 in total

Review 1.  Therapeutic drug monitoring of psychotropic medications.

Authors:  P B Mitchell
Journal:  Br J Clin Pharmacol       Date:  2000-04       Impact factor: 4.335

2.  Poor correlation between single-dose data and steady-state kinetics for phenobarbitone, primidone, carbamazepine and sodium valproate in children during monotherapy. Possible reasons for the lack of correlation.

Authors:  J A Armijo; J L Herranz; R Arteaga; R Valiente
Journal:  Clin Pharmacokinet       Date:  1986 Jul-Aug       Impact factor: 6.447

3.  Plasma concentrations of mianserin after single dose and at steady-state in depressed elderly patients.

Authors:  S Dawling; S Ford; P Ariyanayagam; H O'Neal; R R Lewis
Journal:  Clin Pharmacokinet       Date:  1987-01       Impact factor: 6.447

Review 4.  Clinical relevance of pharmacokinetics.

Authors:  G Tognoni; C Bellantuono; M Bonati; M D'Incalci; M Gerna; R Latini; M Mandelli; M G Porro; E Riva
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

5.  Prediction of steady-state nortriptyline plasma levels by the repeated one-point method.

Authors:  W K Fant; W A Ritschel; S K Alwis; S Roe; J Ehret
Journal:  Clin Pharmacokinet       Date:  1984 Sep-Oct       Impact factor: 6.447

6.  Prediction of maintenance dose required to attain a desired drug concentration at steady-state from a single determination of concentration after an initial dose.

Authors:  J T Slattery; M Gibaldi; J R Koup
Journal:  Clin Pharmacokinet       Date:  1980 Jul-Aug       Impact factor: 6.447

7.  The pharmacokinetics of nortriptyline in patients with chronic renal failure.

Authors:  S Dawlilng; K Lynn; R Rosser; R Braithwaite
Journal:  Br J Clin Pharmacol       Date:  1981-07       Impact factor: 4.335

8.  Clinical pharmacokinetics of dothiepin. Single-dose kinetics in patients and prediction of steady-state concentrations.

Authors:  K P Maguire; T R Norman; I McIntyre; G D Burrows
Journal:  Clin Pharmacokinet       Date:  1983 Mar-Apr       Impact factor: 6.447

9.  Prediction of steady state plasma and saliva levels of desmethylimipramine using a single dose, single time point procedure.

Authors:  T B Cooper; N Bark; G M Simpson
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

10.  Amitriptyline and nortriptyline response profiles in unipolar depressed patients.

Authors:  L S Lehmann; C L Bowden; F C Redmond; B C Stanton
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.